Tetraphase investors have an opportunity to recover their investment losses.
Click "Join this Class Action" above.
Tetraphase Pharmaceuticals, Inc.
Rosen Law Firm announces the filing of a securities class action lawsuit on behalf of purchasers of the common stock and call options and sellers of put options of Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) from March 5, 2015 through September 8, 2015, all dates inclusive (the “Class Period”), resulting from allegations that Tetraphase may have issued materially misleading business information to the investing public.
If you purchased common stock and call options or sold put options of Tetraphase from March 5, 2015 through September 8, 2015 and would like to join the action, please click "Join This Class Action" above.
EQUITY ALERT UPDATE: Rosen Law Firm Expands Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. on Behalf of Options Purchasers and Sellers - TTPH
New York, N.Y., March 23, 2016. Rosen Law Firm, a global investor rights law firm, has filed a class action lawsuit on behalf of all purchasers of the common stock and call options and sellers of put options of Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) from March 5, 2015 through September 8, 2015, all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Tetraphase Pharmaceuticals investors under the federal securities laws.
To join the Tetraphase Pharmaceuticals class action, go to the firm’s website at http://www.rosenlegal.com/cases-830.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email firstname.lastname@example.org or email@example.com for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period misrepresented the efficacy and safety of Eravacycline, and attendant capacity for approval by both the U.S. Food and Drug Administration and the European Medicines Agency. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 28, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation go to the firm’s website at http://www.rosenlegal.com/cases-830.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll-free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827